Palatin Techs (AMEX:PTN) Stock

Palatin Techs

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Tired,Teen,Girl,Rubbing,Dry,Irritable,Eyes,Feel,Eye,Strain

Biotech

Press Releases

General

FDA Confirms Acceptability of Palatin&#39;s Remaining Phase 3 Pivotal Clinical Trials For PL9643 In Dry Eye Disease (DED)

Screenshot 2024-08-28 at 6.22.42 PM

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory &amp;  Autoimmune Conditions, Obesity And Sexual Dysfunctions

Biochemical,Research,Scientist,Team,Working,With,Microscope,For,Coronavirus,Vaccine

First Patient Dosed In Phase 2 Clinical Study Of Palatin&#39;s Bremelanotide Co-Administered With Tirzepatide (GLP-1) For The Treatment Of Obesity

Palatin Technologies Inc

PT Bank CIMB Niaga Tbk

PT VALE INDONESIA TBK by PT Vale Indonesia TBK

PT Vale Indonesia Tbk

PT VALE INDONESA UNSP/ADR by PT Vale Indonesia TBK

PT INDO KORDSA TBK by PT INDO KORDSA TBK

Pacer Trendpilot 100 ETF

PARTNER COMMUNS CO ORD by Partner Communications Company Ltd.

Partner Communications Co Ltd

Partner Communications Co Ltd ADR

PLATINA RESOURCES LTD ORD by Platina Resources, Ltd.

Platina Resources Ltd

ParcelPal Logistics Inc

PARCELPAL LOGISTICS INC by PARCELPAL LOGISTICS INC.

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and lowers the price target from $17 to $7.

News

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Palatin Techs, Lowers Price Target to $7

Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.42) by 71.43 percent. This is a 78.57 percent increase over losses of $(0.56) per share from the same period last year.

Earnings

Earnings Beats

Palatin Techs Q2 2025 GAAP EPS $(0.12) Beats $(0.42) Estimate. Cash And Equivalents Of $3.4M

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Registered Direct Offering") at a purchase price of $1.00 per share.

Penny Stocks

Offerings

Palatin Technologies Announces $4.7M Direct Offering Of 4.688M Shares Of Common Stock At A Price Of $1.00 Each

WIIM

Palatin Technologies shares are trading higher after the company announced the completion of its Phase 2 BMT-801 clinical study of MC4R.

Palatin Technologies Announced The Completion Of Its Phase 2 BMT-801 Clinical Study Of The Co-administration Of MC4R Bremelanotide + GLP-1/GIP Tirzepatide For The Treatment Of Obesity

<h3>Gainers</h3>
<ul>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock increased by 112.1% to $1.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.9 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 62.84% to $1.35. The company's market cap stands at $2.7 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares rose 61.86% to $1.23. The market value of their outstanding shares is at $33.8 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock rose 32.84% to $0.22. The market value of their outstanding shares is at $1.5 million. </li>
<li>Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) stock increased by 19.85% to $25.47. The market value of their outstanding shares is at $3.2 billion. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares rose 13.78% to $0.99. The market value of their outstanding shares is at $23.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 69.2% to $0.45 during Tuesday's pre-market session. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) shares fell 63.54% to $0.82. The market value of their outstanding shares is at $31.4 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares declined by 44.73% to $2.41. The market value of their outstanding shares is at $22.2 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) shares declined by 20.78% to $2.44. The market value of their outstanding shares is at $120.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares fell 16.71% to $0.54. The market value of their outstanding shares is at $4.4 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 12.5% to $1.47. The market value of their outstanding shares is at $257.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKYA

BACK

HEPA

LPTX

ONCO

SABS

SGRY

SLXN

STSS

TRIB

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy</li>
<li>Demonstrated efficacy at 6 months
<ul>
<li>71% percent of patients achieved a &gt;30% reduction in the urine protein to&nbsp;creatinine ratio (UP/Cr)</li>
<li>71% of patients achieved improved or stabilized estimated&nbsp;glomerular filtration rate (eGFR)</li>
</ul>
</li>
<li>Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patients</li>
</ul>

Health Care

Palatin Announced Topline Data From BREAKOUT Phase 2b Study Of Bremelanotide In Diabetic Kidney Disease To Assess The Efficacy In Reducing Urinary Protein And Maintaining Podocyte Density And Function

Financing

Palatin Technologies Entered Into A Warrant Exercise Inducement Agreement With An Institutional Investor To Exercise Certain Outstanding Warrants Issued In June 2024 And October 2023 Totaling 3.91M For Gross Proceeds Of Approximately $3.4M

Palatin Technologies shares are trading higher after the company announced the completion of enrollment in its Phase 2 Study of PL8177.

The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active ulcerative colitis.

Palatin Technologies Has Completed Enrollment In Its Phase 2 Study Of PL8177 For Ulcerative Colitis, The Last Patient Visit Is Expected To Occur In Q1 Of 2025, With Topline Data Expected Shortly Thereafter

Palatin Technologies shares are trading lower. The company reported Q1 financial results.

Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.51) by 23.53 percent. This is a 9.3 percent increase over losses of $(0.43) per share from the same period last year.

Palatin Techs Q1 2025 GAAP EPS $(0.39) Beats $(0.51) Estimate. Cash And Equivalents Of $2.4M

AFMD

AGAE

AIRI

AQMS

AREC

ASND

ASTS

AZUL

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Palatin Techs to report an earnings per share (EPS) of $-0.51.
The announcement from Palatin Techs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.61% drop in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2024/1731521034_0.png" alt="eps graph" />
<h3>Performance of Palatin Techs Shares</h3>
Shares of Palatin Techs were trading at $1.2 as of November 12. Over the last 52-week period, shares are down 34.05%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/PTN/earnings">To track all earnings releases for Palatin Techs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Palatin Techs's Earnings Forecast

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Comments

Palatin Techs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga